---
title: "Sino Biopharmaceutical Unveils HK$2 Billion Share Purchase Plan to Support Stock and Shareholders"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289702409.md"
description: "Sino Biopharmaceutical (HK:1177) announced a HK$2 billion share purchase plan over the next 12 months to support its stock price, citing market undervaluation. The company has already repurchased shares worth HK$338 million this year and maintains sufficient financial resources. Management views this as a demonstration of confidence in its business outlook and aims to boost investor confidence. Analysts currently rate the stock as a Buy with a HK$6.50 target."
datetime: "2026-06-14T22:07:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289702409.md)
  - [en](https://longbridge.com/en/news/289702409.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289702409.md)
---

# Sino Biopharmaceutical Unveils HK$2 Billion Share Purchase Plan to Support Stock and Shareholders

Sino Biopharmaceutical ( (HK:1177) ) has issued an announcement.

Sino Biopharmaceutical’s board has launched a share purchase plan in response to recent share price volatility, arguing that the company’s value is being significantly underestimated by the market. The plan allows for up to HK$2 billion in share purchases over the next 12 months, combining on-market buybacks under an existing mandate and acquisitions for its restricted share award scheme.

The company has already bought 60,350,000 shares this year for about HK$338 million and emphasizes that it has sufficient financial resources to continue the program while maintaining a healthy balance sheet. Management frames the move as a demonstration of confidence in its business outlook and a means to boost investor confidence and enhance shareholder returns, while cautioning investors to be prudent when trading its securities.

The most recent analyst rating on (HK:1177) stock is a Buy  
with a HK$6.50 price target.  
To see the full list of analyst forecasts on Sino Biopharmaceutical stock,  
see the HK:1177 Stock Forecast page.

**More about Sino Biopharmaceutical**

Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical company incorporated in the Cayman Islands, operating in the biopharmaceutical sector. The group focuses on research, development, manufacturing and marketing of pharmaceutical products, serving healthcare markets with a portfolio that supports long-term growth and shareholder value in the industry.

**YTD Price Performance:** -23.95%

**Average Trading Volume:** 79,781,986

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$83.8B

### Related Stocks

- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)

## Related News & Research

- [Sino Biopharm Sets Hybrid AGM, Seeks Fresh Share Issue Mandate](https://longbridge.com/en/news/284532331.md)
- [Sino Biopharm’s Culmerciclib Shows Promise in Resistant Breast Cancer](https://longbridge.com/en/news/288338622.md)
- [Sino Biopharm Advances First-in-Class CCR8 Antibody Into Phase III Gastric Cancer Trial](https://longbridge.com/en/news/285458913.md)
- [Sino Biopharm Showcases Promising Obesity Antibody Data and Expands Weight-Loss Pipeline](https://longbridge.com/en/news/286328735.md)
- [Assessing Veeva Systems (VEEV) Valuation After Recent Share Price Weakness And Fair Value Gap](https://longbridge.com/en/news/289441327.md)